IDNA — IDNA Genomics Public Share Price
Last trade - 00:00- €76.19m
- €77.83m
- €0.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.65 | ||
| Price to Tang. Book | 34.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 178.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.31% | ||
| Return on Equity | -36.98% | ||
| Operating Margin | -314.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | 0.78 | 1.08 | 0.49 | n/a | n/a | -20.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Idna Genomics Public Ltd is a Cyprus-based company primarily engaged in Precision Medicine and Genetic Analysis industry. The Company is engaged in developing and providing genetic analysis for Pharmacogenetics. The Company provides DNA analysis services that allow the general public to gain access to their unique genetic characteristics in a personalized approach. Idna Genomics Public Ltd provides access to simplified and high-quality pharmacogenetics data analysis and advice on clinical interpretation of results. The process of analysis is fully automated by the Company's own platform, which processes biostatistical, bioinformatics, pharmacogenetic and biological data. The results of the analyses are based on published scientific literature from international databases.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 16th, 2020
- Public Since
- December 17th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Cyprus Stock Exchange
- Shares in Issue
- 2,760,333
- Address
- Odos Chatzidaki 7, 3Os Orofos, Trypiotis, NICOSIA, 1066
- Web
- https://idnagenomics.com/
- Phone
- +357 22422240
- Auditors
- ADM Audit Trust Limited
Upcoming Events for IDNA
FAQ
As of Today at 21:13 UTC, shares in IDNA Genomics Public are trading at €27.60. This share price information is delayed by 15 minutes.
Shares in IDNA Genomics Public last closed at €27.60 and the price had moved by +0.73% over the past 365 days. In terms of relative price strength the IDNA Genomics Public share price has underperformed the FTSE Global All Cap Index by -1.79% over the past year.
There is no consensus recommendation for this security.
Find out moreIDNA Genomics Public does not currently pay a dividend.
IDNA Genomics Public does not currently pay a dividend.
IDNA Genomics Public does not currently pay a dividend.
To buy shares in IDNA Genomics Public you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €27.60, shares in IDNA Genomics Public had a market capitalisation of €76.19m.
Here are the trading details for IDNA Genomics Public:
- Country of listing: Cyprus
- Exchange: CYS
- Ticker Symbol: IDNA
Based on an overall assessment of its quality, value and momentum IDNA Genomics Public is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDNA Genomics Public. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +2.09%.
As of the last closing price of €27.60, shares in IDNA Genomics Public were trading +7.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IDNA Genomics Public PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €27.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on IDNA Genomics Public's directors